
Gefitinib
Form: Oral Tablets:
Strength: 250 mg
Reference Brands: Iressa® (EU & US)
Category: Oncology Cancer Care
Gefitinib is a targeted oral therapy used in the treatment of advanced non-small cell lung cancer (NSCLC) with confirmed EGFR mutations. Marketed under the brand name Iressa®, Gefitinib is approved in the EU and US and is widely available as 250 mg tablets. It is an EGFR tyrosine kinase inhibitor that blocks signals promoting tumor cell growth and proliferation. Gefitinib is an essential product in oncology therapy protocols and is frequently used as a first-line treatment for eligible NSCLC patients. Ideal for B2B pharmaceutical distributors seeking high-demand oncology medications in global regulated markets.
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Related Products
Atezolizumab
Strength: 1200 mg/20 mL
Form: Intravenous infusion
Reference Brands: Tecentriq® (EU & US)
View Details Get EnquiryDurvalumab
Strength: 120 mg/4 mL, 500 mg/10 mL
Form: Injection
Reference Brands: Imfinzi® (US & EU)
View Details Get EnquirySunitinib
Strength: 12.5 mg, 25 mg, 37.5 mg, 50 mg
Form: Tablet
Reference Brands: Sutent® (EU & US)
View Details Get EnquiryIfosfamide
Strength: 1 g/vial,2 g/vial, 3 g/vial
Form: Injection
Reference Brands: Ifex® (US), Holoxan® (EU)
View Details Get Enquiry